Articles by Andrea Sporchia
TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi 
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
ByBarbara Pistilli,Livia Pierotti,Magali Lacroix-Triki,Cecile Vicier,Jean-Sebastien Frenel,Véronique D’Hondt,Florence Dalenc,Thomas Bachelot,Agnes Ducoulombier,Marc-Antoine Benderra,Delphine Loirat,Didier Mayeur,Ghada B. Nachabeh,Andrea Sporchia,Fumitaka Suto,Stefan Michiels,Noemie Corcos,Fernanda Mosele,Fabrice André, Guillaime Montagnac
